Ubrogepant

N/A

Report date: 2022/05/11 12:45:03
NME

Base Information

Drug NameUbrogepant
Drug Alias Name乌布吉泮ubrogepantubrogepantum乌洛戈潘Ubrelvy +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcitonin gene-related peptide receptor antagonists
TargetsCalcitonin gene-related peptide receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/12/23
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesAllergan Plc
Active IndicationsMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN02C
Related LinksWikipediaDrugBankKEGG